Ocugen Inc (OCGN) Stock Price, Quote & News

Company Profile

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber c...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 328 4701

Website: www.ocugen.com

Address:

11 Great Valley Parkway, Malvern, United States

MAs_Crxss Mar. 12 at 12:23 AM

$OCGN @Ramanda87 You sound like you’ve been shanked by the shanksta. Get lost noob!!!!!

0 · Reply

ZALEZPHOTO Mar. 12 at 12:08 AM

$OCGN @Ramanda87 brother, any day can be a great day for day traders, and there’s nothing wrong with that. I don’t necessarily disagree with your bigger point on how many people react or handle down days, and be clueless about the spectacle they display. But, you’re also seem clueless on why or what means to go and “play” for the long haul on a great opportunity. Congratulations on taking your daily profit here today. If you asked me, I think anyone who did, will regret not going long on this very particular opportunity. Good Luck, day trading!

1 · Reply

VINCENZOCOCCOTTI Mar. 12 at 12:07 AM

$OCGN 41 million share volume, fake pump my ass you clown

0 · Reply

Dummy1953 Mar. 12 at 12:02 AM

$OCGN Beware. I followed this stock in 2021-2022 and this looks like history is repeating itself. Shankar gifted himself 3 million shares in January.

1 · Reply

mrpauley Mar. 12 at 12:02 AM

$OCGN back in 2022, it went from 2.48 down to 2.26 and then back up to 2.36. Today , we hit 2.36, floating around 2.26, and I'm a simple man. I think it continues the pattern on the way up. There could be a chance we see a drop down to 2.20 area before we move back up, but I def think tomorrow is green by EOD. Ive traded for 15 years and have insane luck following the mirror patterns on floor reversals.

1 · Reply

Martinsucks Mar. 11 at 11:42 PM

$OCGN what happens tomorrow?

1 · Reply

MarjorieHicksa Mar. 11 at 11:40 PM

$OCGN Analyst target price update for today @MarjorieHicksa

0 · Reply

CasaDePapel Mar. 11 at 11:39 PM

$OCGN $2.48 pre market than hard crush! As per usual! Thanks fake bulls for the pump

1 · Reply

FrostFuzz Mar. 11 at 11:26 PM

[Click the link below to join Starlight ⬇️ Hands down the best small-cap community I’ve found 🔥 Completely free to join with no cost. Access is limited, so don’t wait. $OCGN & $CVGI on watchh

0 · Reply

Sw1ngb0t Mar. 11 at 11:24 PM

$OCGN $2.87+

0 · Reply

Ocugen, Inc. (OCGN) Q4 2025 Earnings Call Transcript

Mar 4, 2026, 8:15 AM EST - 7 days ago

Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results

Mar 2, 2026, 7:02 AM EST - 9 days ago

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa

Feb 9, 2026, 7:02 AM EST - 4 weeks ago

Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

Jan 23, 2026, 8:00 AM EST - 6 weeks ago

Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock

Jan 21, 2026, 4:37 PM EST - 7 weeks ago

Ocugen (OCGN) Stock Tumbles After $22.5 Million Share Offering

Jan 21, 2026, 8:32 AM EST - 7 weeks ago

Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock

Jan 15, 2026, 2:16 PM EST - 7 weeks ago

Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy Transcript

Jan 15, 2026, 1:15 PM EST - 7 weeks ago

Ocugen's Early Gene Therapy Data Shows 46% Drop In Vision Damage

Jan 15, 2026, 8:15 AM EST - 7 weeks ago

Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Jan 13, 2026, 7:00 AM EST - 2 months ago

Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

Jan 12, 2026, 6:30 AM EST - 2 months ago

Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy

Jan 9, 2026, 7:02 AM EST - 2 months ago

Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference

Jan 6, 2026, 12:20 AM EST - 2 months ago

Ocugen: Maintaining 'Buy' Rating On Positive OCU410ST Regulatory Developments

Dec 10, 2025, 9:20 AM EST - 3 months ago

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Nov 20, 2025, 7:02 AM EST - 3 months ago

Ocugen CEO to Present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference

Nov 5, 2025, 4:21 PM EST - 4 months ago

Ocugen, Inc. (OCGN) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 6:30 AM EST - 4 months ago

Ocugen Provides Business Update with Third Quarter 2025 Financial Results

Oct 23, 2025, 7:30 AM EDT - 4 months ago

Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results

Sep 23, 2025, 11:11 AM EDT - 6 months ago

Ocugen: A Retinal Disease Juggernaut In The Making

Sep 15, 2025, 4:29 PM EDT - 6 months ago

Ocugen Shares Are Trading Higher Monday: What's Going On?

Sep 15, 2025, 6:03 AM EDT - 6 months ago

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Sep 2, 2025, 7:02 AM EDT - 6 months ago

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

Aug 13, 2025, 6:27 AM EDT - 7 months ago

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

Aug 12, 2025, 3:45 PM EDT - 7 months ago

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

Aug 8, 2025, 5:03 PM EDT - 7 months ago

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

Aug 1, 2025, 12:30 PM EDT - 7 months ago

Ocugen, Inc. (OCGN) Q2 2025 Earnings Call Transcript

Aug 1, 2025, 8:25 AM EDT - 7 months ago

Ocugen Provides Business Update with Second Quarter 2025 Financial Results

Jul 21, 2025, 7:30 AM EDT - 8 months ago

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

Jul 18, 2025, 7:02 AM EDT - 8 months ago

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

Jul 17, 2025, 6:30 AM EDT - 8 months ago

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

Jun 23, 2025, 7:30 AM EDT - 9 months ago

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

Jun 18, 2025, 4:00 PM EDT - 9 months ago

Ocugen: Three Potential Gene-Therapy Filings By 2028

Jun 16, 2025, 7:02 AM EDT - 9 months ago

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

Jun 11, 2025, 7:30 AM EDT - 9 months ago

Ocugen To Present at BIO International Convention 2025

Jun 5, 2025, 7:02 AM EDT - 9 months ago

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

May 27, 2025, 7:02 AM EDT - 10 months ago

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

May 9, 2025, 10:02 AM EDT - 10 months ago

Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript

May 9, 2025, 8:01 AM EDT - 10 months ago

Ocugen Provides Business Update with First Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 11 months ago

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

Apr 29, 2025, 7:30 AM EDT - 11 months ago

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Apr 8, 2025, 8:02 AM EDT - 1 year ago

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

Mar 18, 2025, 8:02 AM EDT - 1 year ago

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Mar 5, 2025, 10:59 AM EST - 1 year ago

Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript

Mar 5, 2025, 7:02 AM EST - 1 year ago

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 8:46 AM EST - 1 year ago

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Feb 21, 2025, 8:00 AM EST - 1 year ago

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Feb 12, 2025, 7:42 AM EST - 1 year ago

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Feb 3, 2025, 6:30 AM EST - 1 year ago

Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

Jan 27, 2025, 6:30 AM EST - 1 year ago

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

MAs_Crxss Mar. 12 at 12:23 AM

$OCGN @Ramanda87 You sound like you’ve been shanked by the shanksta. Get lost noob!!!!!

0 · Reply

ZALEZPHOTO Mar. 12 at 12:08 AM

1 · Reply

VINCENZOCOCCOTTI Mar. 12 at 12:07 AM

$OCGN 41 million share volume, fake pump my ass you clown

0 · Reply

Dummy1953 Mar. 12 at 12:02 AM

$OCGN Beware. I followed this stock in 2021-2022 and this looks like history is repeating itself. Shankar gifted himself 3 million shares in January.

1 · Reply

mrpauley Mar. 12 at 12:02 AM

1 · Reply

Martinsucks Mar. 11 at 11:42 PM

$OCGN what happens tomorrow?

1 · Reply

MarjorieHicksa Mar. 11 at 11:40 PM

$OCGN Analyst target price update for today @MarjorieHicksa

0 · Reply

CasaDePapel Mar. 11 at 11:39 PM

$OCGN $2.48 pre market than hard crush! As per usual! Thanks fake bulls for the pump

1 · Reply

FrostFuzz Mar. 11 at 11:26 PM

0 · Reply

Sw1ngb0t Mar. 11 at 11:24 PM

$OCGN $2.87+

0 · Reply

Pafist Mar. 11 at 11:17 PM

$OCGN Does not disappoint!

0 · Reply

mrpauley Mar. 11 at 11:13 PM

$OCGN I think we go to 2.48 tomorrow.

1 · Reply

Kickapooo Mar. 11 at 11:10 PM

$OCGN can't believe it's been 4 years since we reached these levels. I was around for when we hit $10 and didn't sell, left bag holding for years. Are we actually on the brink of some big moves? Hard to trust these gainz short term but I'm all ears

1 · Reply

DMack427 Mar. 11 at 11:03 PM

$OCGN Still holding 8,000 shares at $8 so there’s that … feel free to moon to $100/share!

1 · Reply

thedavidsonny Mar. 11 at 10:51 PM

$OCGN 🔥 🔥 🔥 Holding Strong $BATL 🔥 🔥 🔥 Running!!! $SGN 🔥 🔥 🔥 Running!!!!

0 · Reply

Ramanda87 Mar. 11 at 10:50 PM

$OCGN this board is hilarious, when it ran up to $2 a week ago the came back down you guys lost your minds. Now it finally breaks $2.30 and instead of taking profits we got folks talking $15 - $100 share

6 · Reply

Fox1Fox2 Mar. 11 at 10:44 PM

$OCGN Conclusion: "...the company has re-entered a phase where the next few quarters genuinely matter, and the stock now has enough analyst sponsorship, pipeline density, and trading energy that each upcoming milestone can move the story much more violently than before."

0 · Reply

stocktraderbegins Mar. 11 at 10:41 PM

$OCGN April 17th - I'm wondering do I cash out, roll the contract to a further date or sell ? Or hold I'm right there at the cusp - Thoughts pls

1 · Reply

bkhlr Mar. 11 at 10:37 PM

$OCGN Trendies

0 · Reply

Upordownwhoknows Mar. 11 at 10:37 PM

$OCGN This has a day where breaks and closes above $3.50 at all this year we touch $16. no resistance after $3.50 really.

1 · Reply

bkhlr Mar. 11 at 10:31 PM

$OCGN "The sell-side boost was the trigger, but the setup underneath was already loaded with real milestones. Analyst attention may have lit the match; management had already stacked the wood."

0 · Reply

CaptSparow Mar. 11 at 10:26 PM

$OCGN I'll just leave this here and I'll have to do the same soon enough. 😂 Do your research folks (read the science) and ignore the noise.

2 · Reply

Market Cap	544.31M
Revenue (ttm)	4.41M
Net Income (ttm)	-67.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,538.55%
Debt to Equity Ratio	8.05

Volume	40,889,500
Avg Vol	5,658,382
Day's Range	N/A - N/A
Shares Out	327.90M
Stochastic %K	50%
Beta	2.75
Analysts	Strong Sell
Price Target	$9.00